[Statement on tuberculosis treatment].
D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000139:chemically induced; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000009:adverse effects / Q000627:therapeutic use; D013882:Thiosemicarbazones / Q000627:therapeutic use
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D013882:Thiosemicarbazones; D011718:Pyrazinamide; D004977:Ethambutol; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Status over tuberkulose-behandlingen.